Page 26

crf_rapport_rgb_singlepage

patient stratifi cation approaches to obtain clinically applicable strategies. Radioprotection of patients and the environment will also be an issue of great importance. A major threat to Related to several of the areas above is research in palliative medicine European leadership in research directed to improve care for seriously ill patients and their families. resides in the decreasing attractiveness of this fi eld for students in several European countries. Europe INSTRUMENTS AND IMPLEMENTATION should improve its attractiveness by taking proactive decisions and In the research area the most important focus is to implement in promote the training of students to experimental approaches and clinical practice, we must however be careful when pushing for im- to data-based decisions very early at school, initiate a strong effort plementation and demand evidence and usefulness. When clinical to propose attractive careers not only at the researcher positions, research has been successfully implemented in clinical practice it but also to create a career path in bio-engineering, and elaborate will answer important questions relevant to clinicians and practition- an intense communication program for researchers to present their ers and provide the evidence necessary to underpin practice. results to the widest audience in all media. Training in the develop- ment of research policy and agendas is further important. An important tool will be European cooperation schemes and the enhancement of student and researcher mobility. Among others, a The Innovative Medicines Initiative (IMI) to remove bottlenecks ham- widely understood taxonomy for research careers across Europe pering the effi ciency of the development of new medicines through will improve scientifi c cooperation. Ideally there should be no public-private partnerships (PPP) is increasingly relevant. Early restrictions preventing researchers in the 27 member states from involvement of the private sector can bring creativity, effi ciency, collaborating, so that the most excellent minds will have the possi- and capital to address complex research questions. bility of working together. Based on an understanding of the value of working in partnership with research communities around the The biomedical companies’ often face severe diffi culties in commer- world, this collaboration should also be set in a global context. cialising their research, with the proliferation of excessively onerous and poorly conceived regulation acting as a major inhibitor to The benefi ts of a common approach for classifying research portfo- innovation. Only few companies have the scale, resources, and lios applied across research organisations are clear. Classifi cation competences to bring new treatments to market, and this lack of helps research organisations keep track and evaluate investments diversity leaves Europe vulnerable. More and more companies are or programmes and, more generally, research policies. The benefi ts fi nding drug development in Europe economically challenging and of successful classifi cation approaches also include improved are moving their operations from the region. This is an issue that communication, the identifi cation of opportunities, the ability to requires a new dynamic between academia, clinical practitioners, compare activity with other research organisations, support for industry, and the regulatory agencies and this has recently been partnership work, and the increased effi ciency of operational addressed successfully via the IMI. processes. The proposal for the Horizon 2020 includes application of exante research classifi cation of funding schemes and expost Biomedical research of high quality should be conducted in an classifi cation of the outcome of research programmes. This is an open, honest, and transparent way and people and patients exceedingly positive and important initiative. should be more greatly involved at all stages. For a more inclu- sive research we need further patient involvement. One way to THE TRIANGLE: Research achieve this is to include and educate members of organizations as research project partners. In NIHs prioritizing and evaluations it is now common practice to include patient advocates. Patient empowerment and advocacy will also be important for translation of new relevant research into clinical practice. Innovation Education is more important in the future than at present and interdisciplinar- ity and collaboration with other research areas and disciplines is of outmost importance for all three sides of the triangle. HEALTH 27


crf_rapport_rgb_singlepage
To see the actual publication please follow the link above